PEDIATRICS Vol. 27 No. 3 March 1961, pp. 351-353
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MATTHEWS, L. W.
Right arrow Articles by SPECTOR, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MATTHEWS, L. W.
Right arrow Articles by SPECTOR, S.

"BREAK-THROUGH IN CYSTIC FIBROSIS"

LEROY W. MATTHEWS M.D.1 and SAMUEL SPECTOR M.D.1

1 Department of Pediatrics, School of Medicine, Western Reserve University, 2103 Adelbert Road, Cleveland 6, Ohio

IT WOULD BE good news indeed if a "break-through through in cystic fibrosis" was really here as has been put forth in the promotional material on Cotazym by Organon, Inc. in an energetic campaign to sell their pancreatic preparation. Uncritical acceptance of unsupported statements in this promotional material would actually be a set-back in the comprehension of present knowledge of cystic fibrosis and the place of pancreatic substitution therapy in the management of patients with this disorder. False hope may be raised in physicians and in the parents of the unfortunate victims of this distressing disease.

Though we do not wish to minimize the importance of the pharmaceutical development of an improved pancreatin preparation we believe that presenting Cotazym as a "break-through in cystic fibrosis" is unwarranted and misleading.